John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), filed a Form 4 on November 3, 2026, disclosing option exercises and open-market sales of Class A Ordinary Shares on October 30 and November 2, 2026, all executed under a Rule 10b5-1 plan.

Key Highlights

  • 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 plan that Paolini executed on July 29, 2026, according to the filing.
  • Options exercised (Oct 30): Paolini exercised 38,545 share options at $30.93 and 39,042 share options at $17.92 on October 30, 2026.
  • Options exercised (Nov 2): Paolini exercised an additional 6,455 share options at $30.93 and 11,958 share options at $17.92 on November 2, 2026.
  • Shares sold (Oct 30): A total of 77,587 Class A Ordinary Shares were disposed of across seven sale transactions on October 30, 2026, at weighted average prices ranging from $92.02 to $97.77.
  • Shares sold (Nov 2): An additional 18,413 Class A Ordinary Shares were disposed of across three sale transactions on November 2, 2026, at weighted average prices ranging from $92.37 to $94.09.
  • Remaining holdings: Following all reported transactions, Paolini directly held 69,922 Class A Ordinary Shares, according to the filing.
  • Options fully vested: The filing states that both the $30.93 option (expiring 09/19/2028) and the $17.92 option (expiring 03/03/2029) were fully vested and exercisable at the time of exercise.

Paolini's Option Exercises and Share Sales Under 10b5-1 Plan

According to the Form 4 filing, Paolini exercised two tranches of fully vested share options on October 30, 2026: 38,545 options with an exercise price of $30.93 and 39,042 options with an exercise price of $17.92. On the same date, the filing reports he sold a combined 77,587 Class A Ordinary Shares across seven separate transactions at weighted average prices between $92.02 and $97.77. Following those October 30 transactions, his directly held share count stood at 69,922.

On November 2, 2026, the filing discloses that Paolini exercised the remaining 6,455 options at $30.93 and 11,958 options at $17.92, fully exhausting both option grants, which then showed zero remaining derivative securities. He also sold 18,413 Class A Ordinary Shares across three transactions on that date at weighted average prices between $92.37 and $94.09, leaving his directly held position at 69,922 Class A Ordinary Shares after all reported activity.

The filing notes that each of the sale transactions was executed in multiple trades through a broker-dealer, and the prices reported are weighted averages. Upon request, Paolini will provide the SEC staff with full details of the number of shares sold at each individual price. All transactions are attributed by the filing to the Rule 10b5-1 plan executed on July 29, 2026. No indirect beneficial ownership is reported.

What Was Disclosed

The filing reports that Kiniksa's Chief Medical Officer John F. Paolini exercised a total of 96,000 share options and sold a total of 96,000 Class A Ordinary Shares across October 30 and November 2, 2026, under a pre-established 10b5-1 plan, retaining 69,922 shares directly held afterward.